武田、Iambic ink人工智能药物发现交易价值超过17亿美元

2026-02-09 23:34

U.S. biotech Iambic on Monday announced a multi-year agreement that could potentially be worth more than $1.7B with Takeda (TAK) to develop small molecule drugs leveraging its AI-led drug discovery technologies.
As part of the partnership, the duo will utilize Iambic’s AI drug discovery models to advance a group of small-molecule drugs initially in the gastrointestinal and inflammation therapeutic areas.
Under the deal, the Japanese drugmaker will also get access to NeuralPLexer, Iambic’s predictive model for protein and protein-ligand structures.
Per the terms, the San Diego-based biotech is eligible to receive upfront research costs and technology access payments in addition to milestone payments that could exceed $1.7B from Takeda (TAK).
The company is also entitled to royalties on net sales of any products commercialized under the deal.

More on Takeda Pharmaceutical